Tagged with Sandoz

China A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’ stock plunge, and BeiGene’s USD 1.33 billion CDK2 inhibitor deal with Ensem Therapeutics.   Bristol Myers to pay $800 million…

Switzerland As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment Humira, the newly spun-off company has been gearing up for its independence by preparing additional biosimilar launches, signing big partnership…

Global After a turbulent five-year tenure, Kare Schultz will be stepping down as the Israeli generics giant ‘s CEO and former Sandoz chief Richard Francis will take over in January. Francis, who brings his vast industry experience at companies like Sandoz and Biogen to the role, will inherit a number of…

UK Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical innovations and the premium costs associated with them. Health inequity and access disparities exist between both rich and developing countries,…

China A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR deal with SciClone Pharmaceuticals.   Moderna holds onto its vaccine IP and refuses tech transfer in China (Financial Times) Moderna…

Global After the prolonged underperformance of its generics division, Sandoz, Novartis has announced a spin off that will allow the company to focus on its core business and which is part of a broader paring down strategy. For Novartis, the separation of Sandoz would further support our strategy of building a…

Spain The outbreak of the COVID-19 pandemic put an end to more than five years of economic growth in Spain. But the country was not alone. Due to strict containment measures, the Europe’s economy went into the greatest recession since the Second World War during the first half of 2020. To…

Europe The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his perspective on recent policy changes at a national and continental level. With over ten years of experience with the company,…

Global In conversation at the FT’s Global Pharmaceutical & Biotechnology Conference last month, Sandoz CEO Richard Saynor outlined the current status of the biosimilars industry, the differences between the European and US markets, the advantages of being part of a large science-based innovator like Novartis, and why competition in biosimilars will…

USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…

Switzerland Sandoz Switzerland’s Jan Tangermann highlights the importance of the Swiss affiliate to the global group and how it was able to provide sustainable and reliable access to critical and essential medicines during the COVID-19 pandemic. Tangermann also makes a compelling case against the implementation of a reference pricing system and…

USA As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM) president & CEO Chip Davis; Carol Lynch, president of Sandoz US, head of Sandoz North America and member of the Sandoz Executive Committee; and Amgen’s biosimilars business…